- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
- Drug · Biological · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Procedural Sedation, Endoscopy
- Interventions
- CNS 7056, Midazolam
- Drug
- Lead sponsor
- Paion UK Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 4 more
- Conditions
- Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Interventions
- RO7198457 intravenous (IV), Observational group (no intervention)
- Drug · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 15
- States / cities
- Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more
- Conditions
- Bipolar Disorder
- Interventions
- ketamine, midazolam
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Hyperpolarized Pyruvate (13C) injection
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- PONV
- Interventions
- APD421- Amisulpride for IV injection, Placebo
- Drug
- Lead sponsor
- Acacia Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
- Interventions
- IMGN151, Carboplatin, Bevacizumab, Olaparib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Teaneck, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 5 more
- Conditions
- Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
- Interventions
- Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Dermatitis, Atopic
- Interventions
- Bermekimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Insulin (Aspart Insulin [Novolog], Regular Insulin)
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Fresno, California • Torrance, California • Orlando, Florida + 8 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, placebo, methotrexate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
- Conditions
- Melanoma
- Interventions
- Palonosetron
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor
- Interventions
- IPN60090, pembrolizumab, paclitaxel, IPN60090 single administration
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Surgery
- Interventions
- Remifentanil, Normal Saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Participants
- Interventions
- AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- TRK-950, Ramucirumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Santa Monica, California + 6 more
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
- Interventions
- Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Migraine
- Interventions
- LY3451838, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
- Interventions
- ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
- Drug
- Lead sponsor
- Enliven Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Plantation, Florida • St Louis, Missouri • Fairfax, Virginia
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Baltimore, Maryland • New York, New York + 4 more